Due to the frequent presence of interstitial lung disease and widespread use of immunosuppressive treatment, systemic sclerosis (SSc) patients may be considered at risk for a more severe disease course and higher mortality when they develop Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) virus infection. Therefore, with World Scleroderma Foundation endorsement, experts from different specialties including rheumatology, virology and clinical immunology gathered virtually to answer to the main practical clinical questions regarding SARS-CoV-2 infection coming from both patients and physicians. This preliminary advice is aligned with other national and international recommendations, adapted for SSc patients.

Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management / Matucci-Cerinic, M.; Bruni, C.; Allanore, Y.; Clementi, M.; Dagna, L.; Damjanov, N. S.; De Paulis, A.; Denton, C. P.; Distler, O.; Fox, D.; Furst, D. E.; Khanna, D.; Krieg, T.; Kuwana, M.; Lee, E. B.; Li, M.; Pillai, S.; Wang, Y.; Zeng, X.; Taliani, G.. - In: ANNALS OF THE RHEUMATIC DISEASES. - ISSN 0003-4967. - 79:6(2020), pp. 724-726. [10.1136/annrheumdis-2020-217407]

Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management

Clementi M.;Dagna L.;Matucci-Cerinic M.
2020-01-01

Abstract

Due to the frequent presence of interstitial lung disease and widespread use of immunosuppressive treatment, systemic sclerosis (SSc) patients may be considered at risk for a more severe disease course and higher mortality when they develop Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) virus infection. Therefore, with World Scleroderma Foundation endorsement, experts from different specialties including rheumatology, virology and clinical immunology gathered virtually to answer to the main practical clinical questions regarding SARS-CoV-2 infection coming from both patients and physicians. This preliminary advice is aligned with other national and international recommendations, adapted for SSc patients.
2020
autoimmune diseases
hydroxychloroquine
scleroderma
systemic
File in questo prodotto:
File Dimensione Formato  
724.full.pdf

solo gestori archivio

Tipologia: PDF editoriale (versione pubblicata dall'editore)
Licenza: Copyright dell'editore
Dimensione 465.41 kB
Formato Adobe PDF
465.41 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11768/135735
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 51
  • ???jsp.display-item.citation.isi??? 49
social impact